Treatment of clinically isolated syndrome: to be PreCISe

The Lancet

Volumn 374, Issue 9700, 2009, Pages 1475-1476

  Miller, David H ^a   Leary, Siobhan M ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; PLACEBO;

ARTICLE; DISEASE COURSE; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICIAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; RELAPSE;

EID: 70350591846     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61453-7     Document Type: Note

References (15)

1. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58 (2005) 840-846
2. Beck R.W., Trobe J.D., Moke P.S., et al., for the Optic Neuritis Study Group. High-and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121 (2003) 944-949
3. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 131 (2008) 808-817
4. Comi G., Martinelli V., Rodegher M., et al., for the PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 10.1016/S0140-6736(09)61259-9 published online Oct 7.
5. Jacobs L.D., Beck R.W., Simon J.H., et al., for the CHAMPS Study Group. Intramuscular interferon beta-1A therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343 (2000) 898-904
6. Comi G., Filippi M., Barkhof F., et al., for the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357 (2001) 1576-1582
7. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
8. Mikol D.D., Barkhof F., Chang P., et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 7 (2008) 903-914
9. Panitch H., Miller A., Paty D., et al., for the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63 (2004) 1788-1795
10. Wolinsky J.S., Narayana P.A., O'Connor P., et al., for the PROMiSe Trial Study Group. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61 (2007) 14-24
11. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
12. DeLuca G.C., Williams K., Evangelou N., Ebers G.C., and Esiri M.M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 129 (2006) 1507-1516
13. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
14. The CAMMS223 Trial Investigators. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359 (2008) 1786-1801
15. Ellis R., and Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?. Mult Scler 15 (2009) 505-508